A large pan‑cancer analysis of 1667 metastatic tumors shows KRAS aberrations in 28.1%, dominated by G12D, G12V and G13D. Mutation type influenced survival, and KRAS amplification varied across tumor types.
buff.ly/ClRCkHG
#KRAS #Oncology #NGS #PrecisionMedicine #TherAdvMedOnc